Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Drug Found to Fight Marfan (Australia)

This article was originally published in PharmAsia News

Executive Summary

Researchers at the Baker Heart Research Institute in Melbourne, Australia, have discovered an existing drug that may be helpful for treating Marfan syndrome. The drug, called perindopril, works to reduce the fragility of the aorta. Aortic rupture is the leading cause of death in people with Marfan, which is a genetic condition that causes imperfections in the connective tissues of the body's skeletal, ocular, and cardiovascular systems. Up until now, most patients with Marfan had to take beta-blockers to slow their heart rate in an attempt to prevent stress on the aorta. But these drugs do nothing to strengthen the aorta and Marfan sufferers often have to undergo multiple heart surgeries, which are both expensive and risky. Scientists say using perindopril will cut down on the need for those surgeries, increasing the quality of life for those with the disease. (Click here for more

You may also be interested in...

Muted Q2 But Biocon Confident Of Insulin Glargine’s Onward US March

Biocon Biologics upbeat on Lantus follow-on’s long revenue stream and prospects for interchangeability, while operational challenges resulted in some supply constraints during the fiscal second quarter.

Coronavirus Vaccines As A Public Good: How Reasonable Is Reasonable?

During a recent press briefing, health officials in China disclosed the country is poised to reach an annual production capacity of 610 million doses for coronavirus vaccines. But they said prices must be based on manufacturing costs and not driven by supply and demand.

Quick Listen: Scrip’s Five Must-Know Things

Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts